Ozagrel

Summary

Ozagrel (CHEMBL11662) is an approved small molecule targeting TBXAS1; indicated across 1 condition including dry eye syndrome.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Targets: 1 (TBXAS1)
• Indications: 1 condition
• Clinical trials: 4
• Chemistry: 228.25 Da · C13H12N2O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL11662
Name	Ozagrel
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	5282440
Molecular formula	C13H12N2O2
Molecular weight	228.25
InChIKey	SHZKQBHERIJWAO-AATRIKPKSA-N

SMILES: C1=CC(=CC=C1CN2C=CN=C2)/C=C/C(=O)O

IUPAC name: (E)-3-[4-(imidazol-1-ylmethyl)phenyl]prop-2-enoic acid

Also known as: KCT-0809, Ozagrel, OZAGREL, Ozagrel sodiumÊ, Ozagrel sodiumÂ, ozagrel

Parent form; salt/anhydrous children: CHEMBL542549

Patent coverage: 1,092 distinct patent families (3,006 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
TBXAS1	CYP5A1	Inhibition	8.22	0.1%	P24557

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Thromboxane-A synthase, Thromboxane-A synthase.

Bioactivity

ChEMBL activities: 11 potent at pChembl ≥ 5 of 11 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
TBXAS1	7.62	IC50	24	nM	CHEMBL_ACT_1026035
TBXAS1	7.62	IC50	24	nM	CHEMBL_ACT_1180087
TBXAS1	7.62	IC50	24	nM	CHEMBL_ACT_624135
TBXAS1	7.22	IC50	60	nM	CHEMBL_ACT_200252
P49430	6.7	IC50	200	nM	CHEMBL_ACT_200255
P49430	6.7	IC50	200	nM	CHEMBL_ACT_200256
TBXAS1	6.52	IC50	300	nM	CHEMBL_ACT_200253
P49430	6.19	IC50	640	nM	CHEMBL_ACT_488478
TBXAS1	6.05	IC50	900	nM	CHEMBL_ACT_200254
TBXAS1	5.85	IC50	1400	nM	CHEMBL_ACT_1057570
TBXAS1	5	IC50	10000	nM	CHEMBL_ACT_299834

Target pathways

Aggregated over 1 target gene(s): TBXAS1.

Top Reactome pathways

13 total, by targets touching each:

Pathway	Targets	Genes
Metabolism	1	TBXAS1
Disease	1	TBXAS1
Biological oxidations	1	TBXAS1
Cytochrome P450 - arranged by substrate type	1	TBXAS1
Phase I - Functionalization of compounds	1	TBXAS1
Eicosanoids	1	TBXAS1
Arachidonate metabolism	1	TBXAS1
Synthesis of Prostaglandins (PG) and Thromboxanes (TX)	1	TBXAS1
Metabolism of lipids	1	TBXAS1
Metabolic disorders of biological oxidation enzymes	1	TBXAS1
Defective TBXAS1 causes GHDD	1	TBXAS1
Diseases of metabolism	1	TBXAS1
Fatty acid metabolism	1	TBXAS1

Dominant GO biological processes

GO term	Targets
prostaglandin biosynthetic process	1
icosanoid metabolic process	1
intracellular chloride ion homeostasis	1
long-chain fatty acid biosynthetic process	1
response to ethanol	1
positive regulation of vasoconstriction	1
prostanoid biosynthetic process	1
response to fatty acid	1
lipid metabolic process	1
fatty acid metabolic process	1
fatty acid biosynthetic process	1
prostaglandin metabolic process	1

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
dry eye syndrome	3	MONDO:0006733	EFO:1000906

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
PHASE2	3
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00200356	PHASE4	COMPLETED	Edaravone-Sodium Ozagrel Comparative Post-Marketing Study on Acute Ischemic Stroke
NCT01211951	PHASE2	COMPLETED	A Study of KCT-0809 in Patients With Dry Eye Syndromes
NCT01427816	PHASE2	COMPLETED	A Phase II Study of KCT-0809 in Patients With Dry Eye Syndrome
NCT01692145	PHASE2	COMPLETED	A Parallel Group Phase II Study of KCT-0809 in Patients With Dry Eye Syndromes

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

45 molecules share ≥1 primary target. Top 45 by shared-target count:

Molecule	Source	Status	Shared targets
3,3’,4’,5-TETRACHLOROSALICYLANILIDE	ChEMBL	Phase 4 (approved)	TBXAS1
AMINOGLUTETHIMIDE	ChEMBL	Phase 4 (approved)	TBXAS1
AMPRENAVIR	ChEMBL	Phase 4 (approved)	TBXAS1
BITHIONOL	ChEMBL	Phase 4 (approved)	TBXAS1
CISPLATIN	ChEMBL	Phase 4 (approved)	TBXAS1
CLOTRIMAZOLE	ChEMBL	Phase 4 (approved)	TBXAS1
DIETHYLSTILBESTROL	ChEMBL	Phase 4 (approved)	TBXAS1
ECONAZOLE	ChEMBL	Phase 4 (approved)	TBXAS1
ERGOTAMINE	ChEMBL	Phase 4 (approved)	TBXAS1
GRAMICIDIN	ChEMBL	Phase 4 (approved)	TBXAS1
HEXACHLOROPHENE	ChEMBL	Phase 4 (approved)	TBXAS1
IMATINIB	ChEMBL	Phase 4 (approved)	TBXAS1
INDOMETHACIN	ChEMBL	Phase 4 (approved)	TBXAS1
KETOCONAZOLE	ChEMBL	Phase 4 (approved)	TBXAS1
MICONAZOLE	ChEMBL	Phase 4 (approved)	TBXAS1
MONTELUKAST	ChEMBL	Phase 4 (approved)	TBXAS1
NELFINAVIR	ChEMBL	Phase 4 (approved)	TBXAS1
NIFEDIPINE	ChEMBL	Phase 4 (approved)	TBXAS1
OXICONAZOLE	ChEMBL	Phase 4 (approved)	TBXAS1
RITONAVIR	ChEMBL	Phase 4 (approved)	TBXAS1
ROSIGLITAZONE	ChEMBL	Phase 4 (approved)	TBXAS1
SAQUINAVIR	ChEMBL	Phase 4 (approved)	TBXAS1
SULCONAZOLE	ChEMBL	Phase 4 (approved)	TBXAS1
SULFASALAZINE	ChEMBL	Phase 4 (approved)	TBXAS1
TAMOXIFEN	ChEMBL	Phase 4 (approved)	TBXAS1
TANNIC ACID	ChEMBL	Phase 4 (approved)	TBXAS1
TROGLITAZONE	ChEMBL	Phase 4 (approved)	TBXAS1
TROVAFLOXACIN	ChEMBL	Phase 4 (approved)	TBXAS1
VINBLASTINE	ChEMBL	Phase 4 (approved)	TBXAS1
ZAFIRLUKAST	ChEMBL	Phase 4 (approved)	TBXAS1
CANDESARTAN	ChEMBL	Phase 3	TBXAS1
INDINAVIR	ChEMBL	Phase 3	TBXAS1
LACIDIPINE	ChEMBL	Phase 3	TBXAS1
ABLUKAST	ChEMBL	Phase 2	TBXAS1
CLOSANTEL	ChEMBL	Phase 2	TBXAS1
DAZMEGREL	ChEMBL	Phase 2	TBXAS1
DAZOXIBEN	ChEMBL	Phase 2	TBXAS1
GENISTEIN	ChEMBL	Phase 2	TBXAS1
IMITRODAST	ChEMBL	Phase 2	TBXAS1
ISBOGREL	ChEMBL	Phase 2	TBXAS1
PIRMAGREL	ChEMBL	Phase 2	TBXAS1
RIDOGREL	ChEMBL	Phase 2	TBXAS1
SAMIXOGREL	ChEMBL	Phase 2	TBXAS1
SULOTROBAN	ChEMBL	Phase 2	TBXAS1
TERBOGREL	ChEMBL	Phase 2	TBXAS1